Literature DB >> 14612534

Inhibiting the expression of DNA replication-initiation proteins induces apoptosis in human cancer cells.

Daorong Feng1, Zheng Tu, Wenyan Wu, Chun Liang.   

Abstract

DNA replication-initiation proteins are expressed in cancer cells, whereas some of these proteins are not expressed in nonproliferating normal cells. Therefore, replication-initiation proteins may present attractive targets for anticancer therapy. Using selected antisense oligodeoxynucleotides and small interfering RNA molecules targeted to the mRNA encoding the DNA replication-initiation proteins hCdc6p, hMcm2p, and hCdc45p, we show that the target genes could be effectively and specifically silenced and that, consequently, DNA replication and cell proliferation were inhibited in cultured human cells. In addition, silencing of these genes resulted in apoptosis in both p53-positive and -negative cancer cells but not in normal cells: cancer cells entered an abortive S-phase, whereas normal cells arrested mainly in G(1) phase. Our studies are the first to suggest that inhibiting the expression of selective replication-initiation proteins is a novel and effective anticancer strategy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14612534

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  42 in total

1.  Widdrol activates DNA damage checkpoint through the signaling Chk2-p53-Cdc25A-p21-MCM4 pathway in HT29 cells.

Authors:  Hee Jung Yun; Sook Kyung Hyun; Jung Ha Park; Byung Woo Kim; Hyun Ju Kwon
Journal:  Mol Cell Biochem       Date:  2011-12-11       Impact factor: 3.396

2.  Stress-stimulated mitogen-activated protein kinases control the stability and activity of the Cdt1 DNA replication licensing factor.

Authors:  Srikripa Chandrasekaran; Ting Xu Tan; Jonathan R Hall; Jeanette Gowen Cook
Journal:  Mol Cell Biol       Date:  2011-09-19       Impact factor: 4.272

3.  Reducing MCM levels in human primary T cells during the G(0)-->G(1) transition causes genomic instability during the first cell cycle.

Authors:  S J Orr; T Gaymes; D Ladon; C Chronis; B Czepulkowski; R Wang; G J Mufti; E M Marcotte; N S B Thomas
Journal:  Oncogene       Date:  2010-05-03       Impact factor: 9.867

4.  The functional role of Cdc6 in S-G2/M in mammalian cells.

Authors:  Eric Lau; Changjun Zhu; Robert T Abraham; Wei Jiang
Journal:  EMBO Rep       Date:  2006-01-27       Impact factor: 8.807

5.  Production of reactive oxygen species in response to replication stress and inappropriate mitosis in fission yeast.

Authors:  Maria A Marchetti; Martin Weinberger; Yota Murakami; William C Burhans; Joel A Huberman
Journal:  J Cell Sci       Date:  2006-01-01       Impact factor: 5.285

6.  Ubiquitylation, phosphorylation and Orc2 modulate the subcellular location of Orc1 and prevent it from inducing apoptosis.

Authors:  Tapas Saha; Soma Ghosh; Alex Vassilev; Melvin L DePamphilis
Journal:  J Cell Sci       Date:  2006-03-14       Impact factor: 5.285

7.  Reduced expression of GINS complex members induces hallmarks of pre-malignancy in primary untransformed human cells.

Authors:  Laura R Barkley; Ihn Young Song; Ying Zou; Cyrus Vaziri
Journal:  Cell Cycle       Date:  2009-05-23       Impact factor: 4.534

8.  Dichotomous metabolism of Enterococcus faecalis induced by haematin starvation modulates colonic gene expression.

Authors:  Toby D Allen; Danny R Moore; Xingmin Wang; Viviana Casu; Randal May; Megan R Lerner; Courtney Houchen; Daniel J Brackett; Mark M Huycke
Journal:  J Med Microbiol       Date:  2008-10       Impact factor: 2.472

9.  Excess MCM proteins protect human cells from replicative stress by licensing backup origins of replication.

Authors:  Arkaitz Ibarra; Etienne Schwob; Juan Méndez
Journal:  Proc Natl Acad Sci U S A       Date:  2008-06-25       Impact factor: 11.205

10.  Origin licensing and p53 status regulate Cdk2 activity during G(1).

Authors:  Kathleen R Nevis; Marila Cordeiro-Stone; Jeanette Gowen Cook
Journal:  Cell Cycle       Date:  2009-06-21       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.